Request FREE sample PDF
Pharmacy benefit management market
HYPERIMMUNE GLOBULIN INJECTION MARKET REPORT OVERVIEW
The global hyperimmune globulin injection market size was USD 1867 million in 2022 and will touch USD 2839.8 million by 2029, exhibiting a CAGR of 6.2% during the forecast period.
Hyperimmune globulins are frequently used to treat vigorous contagions in immunosuppressed masses. Hyperimmune globulins are similar to IVIGs (Intravenous Immunoglobulin) but are prepared by the plasma obtained from donors with high titers of antibodies against a precise antigen or organism. These donors were either naturally infected or exposed to the disease at particular period in the earlier or were preciously vaccinated. Hyperimmune globulin provides passive immunity to the patient against specific agents. This passive immunity has an immediate but short-term effect for protection against the disease, opposed to active immunity offered by the IVIGs, which is preferable in cases where a person is exposed to a live pathogen or injected with a substance containing antigen like the rabies vaccine. Without hyperimmune globulins, several individuals who contract serious diseases would otherwise die.
Even though enhancements in antimicrobial treatments, there are a huge amount of pathogens that remain challenging to treat and others for which no precise chemotherapy occurs. Hence, polyclonal immunoglobulin persists to be used for the dealing of a variation of infectious diseases and infection-related ailments, frequently based on subjective and off-label involvement. Participants are fixing their efforts on encouraging R&D. Technological development are supporting the regional market growth. Companies need to stay modernised with altering market trends and develop products that meet growing consumer needs. Companies coming up with progressive technological solutions for firming their positions.
COVID-19 Impact: Pandemic Hampered The Market Due To Unexpected Disruption In The Sector
The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.
COVID- 19 pandemic has extremely affected the whole world. It caused many unexpected disruption and affected the industry. COVID- 19 had negative impact on the market due to economic slowdown, unpredictability in financial sector and high unstable market. The pandemic resulted in decreased demand due to a disrupted supply chain, drop in sales of products, delivery schedules. Travel bans imposed affected business collaboration and partnership. Demand had recently reduced due to travel bans and lockdown during the COVID-19 pandemic. The continuous loss in the business due to the lockdown measures is projected to directly influence the growth of the investments in the market.
LATEST TRENDS
"Use Of Innovative Products To Boost The Market Growth "
Technological improvement and development will further enhance the presentation of the product, allowing it to obtain a varied range of requests in the market. Technological advancement will improve performance and propel the market growth. Technological advancement with high demand are increasingly setting a force to increase the productivity. Some players focus on product improvement to meet consumer requirements and likings. Constant innovation in manufacturing of products is anticipated to stimulate product demand.
HYPERIMMUNE GLOBULIN INJECTION MARKET SEGMENTATION
By Type Analysis
According to type, the market can be segmented into hepatitis B immunoglobulins, rabies immunoglobulins, tetanus immunoglobulins, Rho(D) immunoglobulins, other
Hepatitis B immunoglobulins will capture the maximum market share through forecast period.
- Hepatitis B Immunoglobulins: These are accurately focused against the hepatitis B virus.
- Rabies Immunoglobulins: They are used for post interaction in person who have been nibbled or hurt by an animal supposed of carrying the rabies virus.
- Tetanus Immunoglobulins: They are managed to individuals who have suffering a tetanus inclined wound and have lacking immunization against tetanus.
- Rho(D) Immunoglobulins: Rho(D) immunoglobulins are used in expecting women to inhibit haemolytic ailment of the infant affected by Rh unsuitability between the mother and fetus.
- Other: It includes hyperimmune globulin products directed against precise diseases such as chickenpox, and breathing syncytial virus immunoglobulins.
By Application Analysis
According to application, the market can be segmented into government institution, private sector, other
Hyperimmune globulin injection market players cover segment as government institution will dominate the market share during forecast period.
- Government Institution: Hyperimmune globulin injections made by government healthcare organisations for community well-being programs, immunization campaigns, and ailment control initiatives.
- Private Sector: The private sector section comprises purchases of hyperimmune globulin injections by reserved healthcare providers, clinics, health centre, and chemist's for use in patient care.
- Other: This category comprises research institutions, charitable organizations involved in healthcare initiatives, and philanthropic aid establishments that allot immunoglobulins in emergency situations or to underserved inhabitants.
DRIVING FACTORS
"Increasing Prevalence Of Infectious Diseases To Boost The Market Growth"
Spreadable ailments persists to upsurge universally the request for hyperimmune globulin injections which are used for passive vaccination against precise pathogens is anticipated to upsurge. The rising occurrence of contagious diseases such as COVID-19 and the necessity for rapid and targeted therapeutic solutions have driven market growth.
"Technological Advancement and Innovation To Upsurge The Market Growth"
Technological advancements and innovation activate unique revenue augmenting opportunity which will upsurge the hyperimmune globulin injection market growth. Growing investment in research and development activities and growing awareness about benefits are expected to deliver profitable opportunities for the market. Improvements in plasma fractionation and distillation skills have enhanced the making and protection of hyperimmune arrangements. Developments in biotechnology have focused to the expansion of more operative methods for making hyperimmune globulin injections resulting in augmented accessibility and affordability of these products.
RESTRAINING FACTOR
"High Cost To Hamper The Market Growth"
Hyperimmune globulin injections can be costly particularly for patients who need continuing or repetitive treatment. The high cost of dealing may limit access to these products predominantly in low-income areas. Technical difficulties will reduce the industry revenue.
HYPERIMMUNE GLOBULIN INJECTION MARKET REGIONAL INSIGHTS
"North America to Dominate the Market Due To Robust Focus On Research & Development"
The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East and Africa.
North America is further expected to witness growth in the hyperimmune globulin injection market share. The region is dominating the market due to robust focus on research and development leading to innovations in biotechnology and medications. The rising inhabitants and increasing income levels are also contributing to the development of the market. Upsurge in investments by key market players for the R&D undertakings and enlargement of their production abilities and product portfolios are projected to upsurge the growth. The expansion of regional market is being aided by technological developments.
KEY INDUSTRY PLAYERS
"Key Players Focus On Partnerships To Gain Competitive Advantage"
The key players are dynamically contributing in strategic events that are aimed at maintaining strong market position and increasing market share by merger, partnerships and others. Key players are motivated to introduce new innovative products. They are spending severely on research and development in order to arise with more new technology so that they can maintain and improve their existing market. The market changes are dynamic such as market expansion, partnership and merger. The collective efforts of these major players expressively impact the competitive landscape and future path of the market.
LIST OF TOP HYPERIMMUNE GLOBULIN INJECTION COMPANIES
- CSL Behring (U.S.)
- Grifols (Spain)
- Biotest (Germany)
- Kedrion (Italy)
- Kamada (Israel)
INDUSTRIAL DEVELOPMENT
March 2020: Grifols, a foremost maker of blood plasma-based products, has arrived a formal collaborated with the US BARDA (Biomedical Advanced Research Development Authority), FDA, and other Federal public health agencies to develop a plasma-derived COVID-19 drug.
REPORT COVERAGE
The report provides scrutiny and information according to market sectors. Business overview, financial overview, product portfolio, new project launch, recent development enquiry are the factors included in the profile. The report incorporates completely examined and appraised evidence of the noticeable players and their position in the market by methods for various descriptive tools. The report covers national and regional level market size and forecast. The report gives businesses the facility to research new prospect in many areas. The report shows to be a functioning tool that players can use to gain a competitive authority over their opponents and ensure durable accomplishment in the market.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 1867 Million in 2022 |
Market Size Value By |
US$ 2839.8 Million by 2029 |
Growth Rate |
CAGR of 6.2% from 2022 to 2029 |
Forecast Period |
2022-2029 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Types & Application |
Frequently Asked Questions
-
What value is the hyperimmune globulin injection market expected to touch by 2029?
The hyperimmune globulin injection market is expected to reach USD 2839.8 million by 2029.
-
What CAGR is the hyperimmune globulin injection market expected to exhibit by 2029?
The hyperimmune globulin injection market is expected to exhibit a CAGR of 6.2% by 2029.
-
What are the driving factors of the hyperimmune globulin injection market?
Increasing prevalence of infectious diseases & technological development and advancement are expected to deliver profitable opportunities for the hyperimmune globulin injection market.
-
What are the hyperimmune globulin injection market segments?
The hyperimmune globulin injection market segmentation that you should be aware of, which include, Based on type the hyperimmune globulin injection market is classified as hepatitis B immunoglobulins, rabies immunoglobulins, tetanus immunoglobulins, Rho(D) immunoglobulins, other. Based on application the hyperimmune globulin injection market is classified as government institution, private sector, other.